These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

573 related items for PubMed ID: 32433676

  • 1. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
    Nguyen DT, Tran TTT, Nghiem NM, Le PT, Vo QM, Day J, Rahman M, Le HM.
    PLoS One; 2020; 15(5):e0233446. PubMed ID: 32433676
    [Abstract] [Full Text] [Related]

  • 2. Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam.
    Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Palecki J, Reddy KR.
    Antivir Ther; 2018; 23(5):415-423. PubMed ID: 29303482
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
    Bhattacharya D, Belperio PS, Shahoumian TA, Loomis TP, Goetz MB, Mole LA, Backus LI.
    Clin Infect Dis; 2017 Jun 15; 64(12):1711-1720. PubMed ID: 28199525
    [Abstract] [Full Text] [Related]

  • 4. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
    Aqel B, Leise M, Vargas HE, Watt KD, Keaveny AP, Zhang N, Zhang N, Pungpapong S.
    Ann Hepatol; 2018 Aug 24; 17(5):815-821. PubMed ID: 30145562
    [Abstract] [Full Text] [Related]

  • 5. Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection.
    Liu CH, Su TH, Liu CJ, Hong CM, Yang HC, Tseng TC, Chen PJ, Chen DS, Kao JH.
    J Gastroenterol Hepatol; 2019 Sep 24; 34(9):1620-1625. PubMed ID: 30693965
    [Abstract] [Full Text] [Related]

  • 6. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P, Wursthorn K, Stoehr A, Atanasov PK, Supiot R, Lee J, Ting J, Petersen J.
    PLoS One; 2019 Sep 24; 14(4):e0214795. PubMed ID: 30946776
    [Abstract] [Full Text] [Related]

  • 7. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS, Liang PC, Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, Dai CY, Hsieh PH, Chuang WL, Yu ML.
    Kaohsiung J Med Sci; 2021 Apr 24; 37(4):334-345. PubMed ID: 33151016
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.
    Kouris G, Hydery T, Greenwood BC, Lavitas P, Price M, Clements K, Alper CJ, Lenz K, Jeffrey PL.
    J Manag Care Spec Pharm; 2018 Jul 24; 24(7):591-597. PubMed ID: 29952708
    [Abstract] [Full Text] [Related]

  • 9. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS, Shahoumian TA, Loomis TP, Mole LA, Backus LI.
    J Hepatol; 2019 Jan 24; 70(1):15-23. PubMed ID: 30266283
    [Abstract] [Full Text] [Related]

  • 10. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    Mizokami M, Dvory-Sobol H, Izumi N, Nishiguchi S, Doehle B, Svarovskaia ES, De-Oertel S, Knox S, Brainard DM, Miller MD, Mo H, Sakamoto N, Takehara T, Omata M.
    J Viral Hepat; 2016 Oct 24; 23(10):780-8. PubMed ID: 27196675
    [Abstract] [Full Text] [Related]

  • 11. Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital.
    Del Rio-Valencia JC, Asensi-Diez R, Madera-Pajin R, Yunquera-Romero L, Muñoz-Castillo I.
    Rev Esp Quimioter; 2018 Feb 24; 31(1):35-42. PubMed ID: 29376623
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
    Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT, Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) A5327 Study Team.
    Clin Infect Dis; 2019 Jul 18; 69(3):514-522. PubMed ID: 31220220
    [Abstract] [Full Text] [Related]

  • 15. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD, Wang ML, Chen EQ, Wu DB, Tao YC, Zhang DM, Tang H.
    Eur J Gastroenterol Hepatol; 2019 Mar 18; 31(3):382-388. PubMed ID: 30383554
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Moser S, Kozbial K, Laferl H, Schütz A, Reiberger T, Schwabl P, Gutic E, Schwanke C, Schubert R, Luhn J, Lang T, Schleicher M, Steindl-Munda P, Haltmayer H, Ferenci P, Gschwantler M.
    Eur J Gastroenterol Hepatol; 2018 Mar 18; 30(3):291-295. PubMed ID: 29120906
    [Abstract] [Full Text] [Related]

  • 17. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Müllhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, Dvory-Sobol H, Denning J, Arterburn S, Pang PS, Brainard D, McHutchison JG, Dufour JF, Van Vlierberghe H, van Hoek B, Forns X, SOLAR-2 investigators.
    Lancet Infect Dis; 2016 Jun 18; 16(6):685-697. PubMed ID: 26907736
    [Abstract] [Full Text] [Related]

  • 18. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, Tran A, Larrey DG, Ratziu V, Alric L, Hyland RH, Jiang D, Doehle B, Pang PS, Symonds WT, Subramanian GM, McHutchison JG, Marcellin P, Habersetzer F, Guyader D, Grangé JD, Loustaud-Ratti V, Serfaty L, Metivier S, Leroy V, Abergel A, Pol S.
    Lancet Infect Dis; 2015 Apr 18; 15(4):397-404. PubMed ID: 25773757
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ, Hyland RH, An D, Svarovskaia E, Pang PS, Brainard D, Stedman CA.
    Gastroenterology; 2015 Nov 18; 149(6):1454-1461.e1. PubMed ID: 26261007
    [Abstract] [Full Text] [Related]

  • 20. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Globke B, Raschzok N, Teegen EM, Pratschke J, Schott E, Eurich D.
    Transpl Infect Dis; 2017 Feb 18; 19(1):. PubMed ID: 27943544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.